Base Molecular Resonance™ Technologies Introduces Game-Changing Solution to Stop Mass Livestock Culling Amid Bird Flu Crisis
STUART, Fla., March 13, 2025 /PRNewswire/ -- In response to the escalating crisis of mass poultry culling due to avian influenza (bird flu), Base Molecular Resonance™ Technologies (BMRT) today announced a breakthrough application of its multi-patented Base Molecular Resonance™ (BMR™) technology that can detect infected animals instantly, eliminating the need for indiscriminate mass slaughter. With this revolutionary advancement, BMRT is poised to transform disease detection in food supply chains, preserving global food security while reducing economic and environmental waste.
The Cost of Bird Flu: Financial and Agricultural Impact
Since the onset of the current avian influenza outbreak, more than 166 million birds, including chickens and turkeys, have been culled in the United States many of which were not infected. Testing data indicates that only 5-10% of these birds would have likely tested positive for the virus. In the last quarter alone, over 20 million egg-laying chickens were culled, further tightening egg supplies and driving up prices. These indiscriminate culling practices have cost poultry farmers hundreds of millions of dollars, impacting food production and straining supply chains.
As a result, egg prices have surged in response from $2.50 to $5.63, reaching as high as $12 in some areas. BMRT's technology provides an immediate and scalable solution to this crisis by enabling real-time precision-based disease detection, ensuring that only infected birds are culled while healthy flocks remain intact.
Preventing Unnecessary Livestock Loss with Precision Scanning
The current approach to containing avian influenza involves mass culling, often resulting in the destruction of millions of birds, many of them perfectly healthy. BMRT's non-invasive, instantaneous scanning technology provides an alternative that distinguishes infected birds from healthy ones in real time, preventing unnecessary destruction of food supplies while maintaining disease control.
According to Robert 'Bo' Short, BMRT Co-Founder & CEO, 'Right now, millions of chickens are being slaughtered out of fear rather than necessity. Our technology eliminates that uncertainty. With a simple scan, we can pinpoint infected animals with 100% accuracy, allowing farmers and regulators to respond with surgical precision instead of widespread devastation. This is a major step forward for global food security, animal welfare, and the agricultural economy.'
Expanding to Cattle, Pork, and Beyond
Beyond poultry, BMRT's molecular resonance technology can be adapted to detect diseases in cattle, swine, and other livestock, helping to prevent devastating outbreaks such as Mad Cow Disease, African Swine Fever, and Foot-and-Mouth Disease to name a few. With food supply disruptions becoming an increasing global concern, BMRT's cutting-edge detection capabilities have the potential to redefine safety standards across the agricultural sector.
'Bird flu is just the beginning,' added Lee Duke, BMRT Co-Founder & President. 'We can detect disease in livestock at the molecular level before symptoms even appear, allowing for rapid intervention that safeguards the food supply and protects farmers from catastrophic losses. This is the future of disease detection.'
Independently Validated for Unmatched Accuracy
BMRT's technology has been independently validated by a third-party study conducted by the Center for Applied Innovation at York St. John University in England. The landmark study confirmed BMRT's 100% accuracy in detecting gunpowder, illegal drugs, cancer and other threats in both blind and double-blind tests, with no false positives or false negatives. The same precision and reliability now apply to disease detection in the agricultural industry, making it possible to safeguard global food supplies with unprecedented efficiency.
A New Era for Agriculture and Food Security
As governments, regulatory agencies, and food producers struggle to contain the economic and ethical fallout of mass livestock culling, BMRT's solution offers a revolutionary path forward. By deploying this safe, rapid, and non-invasive screening technology, the industry can replace fear-driven responses with precision-based disease management, ensuring food stability without compromising public health.
About Base Molecular Resonance™ Technologies (BMRT)
BMRT has discovered a new area of Quantum Physics that utilizes resonant frequencies to detect particle interactions at subatomic levels. This technology, called Base Molecular Resonance™ (BMR™), can detect any compound or biological substance, including every element on the periodic table, and up to 200 cancers and other diseases. With over 20 years of prototyping and testing proving its unmatched detection capabilities, BMR™ has the potential to save millions of lives by pinpointing weapons, explosives, and other physical threats both up close and at great distances, and detecting cancers and other diseases long before they present clinical symptoms. The non-invasive, harmless, and instant scan has broad implications in cancer diagnostics, public safety, law enforcement, security, and military services.
Bryan Adams
800.522.4718 Ext. 1
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights
Hematologists are poised to jump on new market entrants once available, as high unmet need and frustration with current treatment standards persist in w-AIHA. EXTON, PA, July 29, 2025 (GLOBE NEWSWIRE) -- According to new findings from Spherix Global Insights' syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune hemolytic anemia (w-AIHA) continue to face clinical complexity, a lack of clear treatment algorithms, and suboptimal outcomes across large segments of their patient population. w-AIHA is a rare hematologic condition in which the body's immune system produces antibodies (primarily IgG) that target and destroy red blood cells at normal body temperatures. It is the most common subtype of autoimmune hemolytic anemia, representing approximately 60–70% of AIHA cases. While the exact prevalence remains difficult to pinpoint, recent research estimates the annual incidence at 1–3 cases per 100,000 individuals in the US.1 Insights from a recent survey of 55 hematologists and 8 in-depth physician interviews reveal that nearly half of patients with w-AIHA are not optimally managed, and only one-quarter maintain stable hemoglobin levels above 10 g/dL. While steroids remain the default first-line treatment, physician satisfaction remains low, with many calling for steroid-sparing options that deliver longer-lasting control and address refractory disease. Hematologists also report significant logistical and clinical hurdles, including delayed referrals, reliance on emergency care for diagnosis, and poor insurance coverage contributing to suboptimal care. Comorbidities such as hypertension, obesity, and acute anemia further complicate management in an already fragile population. The future treatment landscape, however, may offer new hope. Physicians highlighted a strong interest in several late-stage pipeline therapies, including nipocalimab (Johnson & Johnson), rilzabrutinib (Sanofi), and ianalumab (Novartis), with each seen as potentially meaningful advances. Physicians approximate that nearly half of their patients may be candidates for at least one of these agents, citing excitement around novel mechanisms, potential for sustained efficacy, and ability to reduce steroid dependence. As hematologists await more definitive guidance and data, they remain aligned in their call for treatments that can deliver durable response, safety, and flexibility across varying levels of disease severity. The w-AIHA space is poised for disruption, but not without overcoming entrenched beliefs and real-world access barriers. Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the service evaluates current treatment approaches, unmet needs, and likely impact of pipeline agents over a three-to-five-year horizon. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284


Business Wire
2 hours ago
- Business Wire
Saltgrass Advisory Launches to Power the Next Wave of Healthcare AI Innovation
CHARLESTON, S.C.--(BUSINESS WIRE)--Saltgrass Advisory, a strategic management consulting firm focused on artificial intelligence and emerging healthcare technologies, today announced its official launch. The firm partners with healthcare institutions, startups, and investors to accelerate high-impact innovation by turning cutting-edge capabilities into scalable, real-world solutions. 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations - health solutions, Medical University of South Carolina. Saltgrass Advisory is led by seasoned executives who bring a rare blend of healthcare, data, and AI expertise. Robert Goodman leverages his track record as a data & AI leader at Deloitte and as an executive within Blackstone-and Vista-backed technology companies. Brian Litten draws on decades as a healthcare operator, including a successful NASDAQ IPO with Tabula Rasa in 2016, his roles as CEO of PathForward Oncology and Swift Medical, and deep leadership experience across the Blue Cross network. Together they're positioning Saltgrass as a trusted partner to drive healthcare innovation at scale. With AI evolving rapidly—and healthcare organizations under growing pressure to deliver better outcomes at lower cost—Saltgrass Advisory enters the market at a pivotal time. The firm guides leaders through this transformation with a focus on intelligent infrastructure, clinical relevance, and operational execution. Impact in Action Saltgrass Advisory is already delivering measurable impact, recently guiding the Medical University of South Carolina (MUSC) on the commercialization of its oncology AI platform, LAMPER, which has driven: an 80% reduction in support staff burden per patient, a 10–20% increase in clinical trial accrual, and 3–4 hours saved per patient across roles. Time-to-appointment readiness has dropped from 1–2 days to under a day. In just one department at MUSC, LAMPER is projected to deliver $2.1M–$10.2M in cost savings over five years, while unlocking new revenue through increased patient throughput and clinical trial enrollment. 'Saltgrass Advisory brought the strategic insight and healthcare expertise we needed to define and commercialize our oncology AI innovation,' said Brett Berman, director of operations, MUSC Health. 'Their team translated academic discovery into real-world impact.' Focused Expertise at the Intersection of Strategy, Technology, and Delivery Saltgrass Advisory—powered by a leadership team of seasoned operators who've built, scaled, and exited companies across the healthcare ecosystem—helps clients accelerate outcomes and unlock healthcare value: Commercialization and go-to-market execution AI strategy, data platforms, intelligent models, seamless integrations, and scalable operations Fractional leadership across product, operations, technology, and growth 1:1 advisory for institutional leaders and startup founders Regulatory, compliance, and policy navigation The Saltgrass Team Brian Litten, Managing Partner – Former digital health founder & CEO Robert Goodman, Managing Partner – Former data & AI executive at Deloitte Lisa Davis, Principal– Past CIO of top U.S. health plan; Former SVP, Intel Health Solutions Munish Khaneja, MD, Principal – Former health plan CMO, EmblemHealth and HealthEdge Drew Narayan, Principal – Former strategy leader at Blue Cross Blue Shield of North Carolina Archana Puthran, Principal – Former AI & digital health leader at UnitedHealth, OptumRx Jacob Jesson, Principal – Former EVP & chief revenue and experience officer, Medecision Paige Bagby – Principal - Former Ogilvy communications and public relations leader Speaker Series Saltgrass Advisory is live, and so is its new speaker series highlighting concrete steps to scale health AI. The series debuts August 19 at 11 a.m. ET. Register here. About Saltgrass Advisory
Yahoo
2 hours ago
- Yahoo
JotPsych Secures $5M Seed Round from Base10 Partners, Fast-Tracking Transition to First Fully Agentic EHR
WASHINGTON, July 29, 2025 /PRNewswire/ -- JotPsych, creator of the leading AI scribe for behavioral health, today announced it has raised $5 million in seed funding led by Base10 Partners. JotPsych's core initial offering is an AI-scribe for behavioral health providers. The software reduces documentation time by 90%+ and is radically customizable and responsive to clinician's preferences and behaviors. In 2024, JotPsych grew by over 1300% and has now processed over 1,000,000 patient encounters. Base10's commitment positions JotPsych to rapidly transform from a best-in-class AI scribe into the first fully agentic Electronic Health Record (EHR). Founded by CEO Nathan Peereboom and CTO Jackson Bierfeldt in 2023, JotPsych launched with a singular goal: to fully eliminate administrative tasks for behavioral health clinicians. The AI scribe functionality was always step one of a broader vision: to become the "spinal cord" of every clinic, automating scheduling, billing, e-prescriptions, care coordination, and more under one "agentic" umbrella. "When we launched JotPsych, our mandate was simple: slash the 4+ hours a day clinicians waste on narrative paperwork," said CEO and Co-Founder Nathan Peereboom. "Now, with Base10's support, we're shifting into high gear to build the first AI EHR that streamlines every leg of the patient journey. By removing any liquidity concerns for the foreseeable future, this partnership grants us our most precious resource: focus." Base10's investment will accelerate product velocity—enabling JotPsych to hire engineering talent, ramp up research and development, and offer a more complex product to customers. JotPsych's upcoming features will integrate intake forms, automated coding and billing, prescription management, and intelligent scheduling, all while leveraging real-time patient data to dramatically reduce the burden on clinicians and improve patient outcomes. "We believe AI will transform healthcare, and JotPsych has the right team, technology, and traction to lead that charge," said Rexhi Dollaku, General Partner at Base10 Partners. "In the next few years, there will be a landgrab among agentic EHR solutions—platforms that don't just document care but actively orchestrate it. JotPsych is positioned to pioneer this new era." About JotPsychJotPsych (SmartScribe Corp) is a healthtech startup pioneering the first fully agentic EHR. JotPsych's AI platform eliminates administrative overhead, allowing clinicians to focus on patient care. For more information, visit About Base10 Partners Founded by Adeyemi Ajao and TJ Nahigian, Base10 is a San Francisco-based venture capital fund investing in founders who believe purpose is key to profits and in companies that are automating sectors of the Real Economy. Through its program the Advancement Initiative, Base10 donates a portion of firm profits to underfunded colleges and universities to support financial aid and other key initiatives. Portfolio companies include Notion, Figma, Stripe, Popmenu, and Nowports. Connect via For media or career inquiries, please reach out to contact@ View original content: SOURCE JotPsych Sign in to access your portfolio